Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: SpanyolországFázis nélkül

Polycystic Ovary Syndrome in Type 1 Diabetes

A legfontosabb adatok

Ki végzi
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Hol
Madrid (Spanyolország)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
60 fő, tervezett
Kezdés
2026. ápr. 1.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Megfigyeléses, 5 csoport
A vizsgált kezelések
  • Type 1 diabetes mellitus
  • Elevated circulating androgen levels
  • Sex dimorphism
A regiszteradat frissítve
2026. szeptember 3.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 18 és 45 év közötti felnőtteket keres öt csoportban: 1-es típusú cukorbeteg nőket és férfiakat, PCOS-sel élő nőket és egészséges kontroll nőket.

Életkor
18 és 45 év között.
Nem
Nők és férfiak is csatlakozhatnak a csoporttól függően (négy csoportban csak nők, az 1-es típusú cukorbeteg férfiak csoportjában csak férfiak).
A betegség stádiuma
Az 1-es típusú cukorbeteg csoportokban legalább 12 hónappal korábban diagnosztizált 1a típusú cukorbetegség, pozitív autoimmunitással és teljes inzulinhiánnyal. A PCOS csoportokban a 2012-es amerikai NIH konszenzus kritériumai szerint felállított PCOS diagnózis.
Korábbi kezelés
Az 1-es típusú cukorbeteg csoportokban bőr alá adott inzulinkezelés (több adag vagy pumpa) szükséges. A nők nem szedhettek fogamzásgátló tablettát vagy glükokortikoidot a belépés előtti 3 hónapban (a női csoportoknál szerepel).
Biomarker vagy leletérték
Pozitív autoimmunitás, amely igazolja az 1a típusú cukorbetegséget. Legalább a belépés előtti hónapra vonatkozó szövetközti glükózmérési adatok.

A részvétel fő kizáró okai

  • Az 1-es típusú cukorbetegség nászút (honeymoon) szakasza
  • Terhesség vagy szoptatás (a női csoportoknál)
  • Pajzsmirigyhormon-zavar vagy magas prolaktinszint
  • Nem klasszikus veleszületett mellékvese-túlműködés vagy a magas androgénszint más oka
  • Más súlyos krónikus betegség

A regiszter feltételei, szó szerint

Mind a 37 feltétel megnézéseKevesebb

Ki vehet részt

  • Age between 18 and 45 years old
  • Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency
  • Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion)
  • Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry

Ki nem vehet részt

  • Diagnosis of other serious chronic disease. reatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study
  • Menarche at least three years prior to study entry
  • Previously known carbohydrate metabolism abnormalities (prediabetes or type 2 diabetes)
  • Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study
  • Menarche at least three years prior to study entry
  • Previously known carbohydrate metabolism disturbances
  • Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study
  • Diagnosis of other serious chronic disease
  • Diagnosis of other serious chronic disease
  • Men with T1D and normal gonadal function of similar age, BMI, and duration of diabetes
  • Women with PCOS of similar age and BMI. INCLUSION CRITERIA
  • Women between 18 and 45 years old
  • Non-hyperandrogenic control women with regular menses of similar age and BMI. INCLUSION CRITERIA
  • Women between 18 and 45 years old
  • Honeymoon period of T1D
  • Pregnancy/lactation
  • Thyroid hormone dysfunction or hyperprolactinaemia
  • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism
  • Honeymoon period of T1D
  • Thyroid hormone dysfunction or hyperprolactinaemia
  • Diagnosis of non-classical congenital adrenal hyperplasia
  • Diagnosis of male hypogonadism
  • PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS
  • Pregnancy/lactation
  • Thyroid hormone dysfunction or hyperprolactinaemia
  • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism
  • Presence of regular menses
  • Lack of signs or symptoms of functional hyperandrogenism. EXCLUSION CRITERIA
  • Pregnancy/lactation
  • Thyroid hormone dysfunction or hyperprolactinaemia
  • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism

Egyéb feltételek

  • Non--hyperandrogenic women with type 1 diabetes INCLUSION CRITERIA; Premenopausal women between 18 and 45 years old; Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency; Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion); Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry; Menarche at least three years prior to study entry. EXCLUSION CRITERIA; Honeymoon period of T1D; Pregnancy or lactation; Thyroid hormone dysfunction or hyperprolactinaemia; Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism; Diagnosis of other serious chronic disease; Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study
  • Women with type 1 diabetes and polycystic ovary syndrome INCLUSION CRITERIA; Women between 18 and 45 years old; Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency; Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion); Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry; Menarche at least three years prior to study entry; PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 45 év között vagy?

Helyszínek itt: Spanyolország

  • Department of Endocrinology and Clinical Nutrition, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, Km 9.1, 28034-Madrid (Spain)Madrid, SpanyolországContact: Manuel Luque-Ramírez, MD, PhD, MBARésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

BACKGROUND Functional ovarian hyperandrogenism, including the polycystic ovary syndrome (PCOS), is very prevalent in women with type 1 diabetes (T1D). The pathogenic mechanisms of this association remain unclear.

A teljes eredeti leírásKevesebb

HYPOTHESIS Individual factors expose or protect women with T1D to/from the development of androgen excess and PCOS. Such androgen excess in women with T1D may increase their cardiometabolic risk.

MAIN OBJECTIVE Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex/gender-medicine and sexual dimorphism perspective.

MATERIAL AND METHOS We have designed a cross-sectional comparative clinical study, including 5 groups of study subjects with 12 participans per group:

i) Women with T1D \& PCOS. ii) Women with T1D without PCOS. iii) Men with T1D and normal gonadal function. iv) Women with PCOS without diabetes mellitus v) Non-hyperandrogenic control women without T1D. All groups will show similar age and body mass index. T1D groups will be matched for duration of disease.

OUTCOMES 1.1 Insulin sensitivity (hyperinsulinaemic euglycaemic clamping). 1.2 Body composition (dual-energy x-ray absorptiometry, bioelectrical impedance analysis \& sonographic studies).

1.3 Ovarian and adrenal steroidogenesis. 2.1 Differential pattern in genetic variants related with insulin signalling and response, inflammation, adiposity, gonadal function, steroidogenesis, and PCOS itself by whole exome sequencing.

2.2 Microbiopsy studies in deep subcutaneous adipose tissue and skeletal muscle tissue: 2.2.1 Differential DNA methylation patterns in genes associated with PCOS. 2.2.2 Differential transcriptomic pattern in genes associated with PCOS.

2.2.3 Differential proteomic patterns in adipose and muscle tissues. 3. Interaction between T1D and PCOS on parameters of metabolic control (intersticial blood glucose monitoring) and morbidities associated with T1D itself.

A vizsgálat 5 csoportja

  • Non--hyperandrogenic women with type 1 diabetes

    INCLUSION CRITERIA * Premenopausal women between 18 and 45 years old. * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency. * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion). * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. * Menarche at least three years prior to study entry. EXCLUSION CRITERIA * Honeymoon period of T1D. * Pregnancy or lactation. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

    Kezelés: Type 1 diabetes mellitus és Sex dimorphism

  • Women with type 1 diabetes and polycystic ovary syndrome

    INCLUSION CRITERIA * Women between 18 and 45 years old. * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency. * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion). * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. * Menarche at least three years prior to study entry. * PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS. EXCLUSION CRITERIA * Honeymoon period of T1D. * Pregnancy/lactation. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. reatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

    Kezelés: Type 1 diabetes mellitus, Elevated circulating androgen levels és Sex dimorphism

  • Men with T1D and normal gonadal function of similar age, BMI, and duration of diabetes.

    INCLUSION CRITERIA * Age between 18 and 45 years old. * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency. * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion). * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. EXCLUSION CRITERIA * Honeymoon period of T1D. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia. * Diagnosis of male hypogonadism.

    Kezelés: Type 1 diabetes mellitus, Elevated circulating androgen levels és Sex dimorphism

  • Women with PCOS of similar age and BMI.

    INCLUSION CRITERIA * Women between 18 and 45 years old. * Menarche at least three years prior to study entry. * PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS. EXCLUSION CRITERIA * Pregnancy/lactation. * Previously known carbohydrate metabolism abnormalities (prediabetes or type 2 diabetes). * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

    Kezelés: Elevated circulating androgen levels és Sex dimorphism

  • Non-hyperandrogenic control women with regular menses of similar age and BMI

    INCLUSION CRITERIA * Women between 18 and 45 years old. * Menarche at least three years prior to study entry. * Presence of regular menses. * Lack of signs or symptoms of functional hyperandrogenism. EXCLUSION CRITERIA * Pregnancy/lactation. * Previously known carbohydrate metabolism disturbances. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

    Kezelés: Sex dimorphism

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Pathogenesis of Functional Hyperandrogenism in Women With Type 1 Diabetes Mellitus: From Genetic-molecular Mechanisms to Clinical Phenotype.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Kérdések a feltételekről
Forrás: NCT07490964: ki vehet részt
A regiszteradat frissítve
2026. szeptember 3.